Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Protocol ID
EZH102
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
Relapse/ refractory
Location
QLD
Sponsor
Epizyme, Inc.
Trial Status
Open
Sites
Queensland Children's Hospital
Study Type
Treatment
Phase
Phase 1
Age Eligibility
6 months to 21 years
International registry ID's
NCT02601937
Back to Registry
Study Title A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Protocol ID EZH102
Disease (Sub Disease) Solid tumours
Diagnosis Stage Relapse/ refractory
Location QLD
Sponsor Epizyme, Inc.
Links https://clinicaltrials.gov/ct2/show/NCT02601937
Trial Status Open
Trial Open Date 27/05/2016
Sites Queensland Children's Hospital
Study Type Treatment
Phase Phase 1
Age Eligibility 6 months to 21 years
International registry ID's NCT02601937